The Dermatology Market Outlook to 2013

Competitive Landscape, Pipeline Analysis and Growth Opportunities

Publication Date	October 2008
Publisher	Business Insights
Product Type	Report
Pages	170
ISBN Number	not applicable
Product Code	RBI00262

Buy this product or for assistance call +44 20 7060 7474

PDF £2,305.00$3834 | €2580

FAX Order above formats by FAX

Summary

The dermatology market remains highly competitive, with developers ranging from Big Pharma to biotechnology and specialty pharmaceutical firms. In recent years levels of innovation in the area have dwindled, allowing generic competition to erode the market share of several leading brands across major drug classes. As leading players continue to lose ground to smaller, specialised players, opportunities are being created for companies that can implement effective lifecycle management and identify lucrative niches.

'The Dermatology Market Outlook to 2013 is a new report published by Business Insights that provides comprehensive coverage across key dermatology markets, with analysis of major currently marketed and pipeline drugs. The growth drivers and competitive dynamics of the area are assessed, with revenue and epidemiological forecasts provided for the period 2008-13. This report assesses the 10 leading companies in the dermatology market, examining their product portfolios and R&D pipelines to provide forecasts of their future competitive positions. This report also assesses prevalence rates across the seven major markets in addition to highlighting key trends across the global dermatology area, with coverage of over 95% of the total market.

Discover the key trends and growth drivers of the market for dermatology treatments, assess the competitive dynamics of leading companies and evaluate the future prospects of major products...

Some key findings from this report

Increased safety concerns will restrict future growth for topical immunosuppressants such as Novartis Elidel and Astellas Protopic. Both these products have a declining market presence due to the FDAs black box label warning in 2005 for potential cancer risk.
Major branded oral acne treatments including Roaccutane will face growing generic competition over the 2008-2013 period. Leading brands in the topical acne treatment market are only expected to achieve marginal growth, while the total market for acne treatments is expected to amass $3b of revenue in 2013.
The market for psoriasis treatments is forecast to register strong growth between 2008-2013, driven by the performances of key drugs such as Raptiva, Taclonex, Soriatane.
The corticosteroid market is estimated to value $3.7b by 2013. Reformulated combination corticosteroid/anti-infective brands will continue be integral to the treatment of psoriasis and dermatitis and will continue to be the primary growth drivers within the area.
Leo Pharma is believed to feature the strongest R&D pipeline in the dermatology market, with five projects currently in the mid to late stages of development. However, most leading companies have sparsely populated pipelines.

Top reasons to order your copy today

Assess the epidemiology and forecast prevalence of major dermatological disorders including acne, psoriasis, dermatitis, rosacea across key geographies including the UK, Japan, France, Germany, Italy, Spain and the US.
Evaluate the performances and strategies of major dermatology developers by examining the sales focus by drug class, currently marketed products and R&D portfolios of Bayer Schering, Galderma, GSK, Leo Pharma, Novartis, J&J, Roche, Sanofi-Aventis, Schering-Plough and Stiefel Labs.
Examine the market dynamics for the global dermatology area and assess key trends and growth drivers across major treatment classes including corticosteroids, topical anti-infectives, acne and psoriasis.
Forecast revenues for major currently marketed and pipeline dermatology products over 2008-13, with this reports sales forecasts across major indications, treatment classes and company portfolios.
Identify the strategies that offer the greatest potential for success in the future, measure the impact of recent key events in the dermatology area and understand the latest issues affecting R&D.

Key issues examined in this report

Generics threaten branded oral acne treatments. The majority of anti-acne brands, excluding Roaccutane and Diane, are based on generic molecules and formulations. This is expected to cause a shift in developmental focus to topical acne treatments and lead to a collapse in the value of the branded oral acne market.
The future of corticosteroids. Triple combination products and reformulations are continuing to revive the sales of corticosteroid brands following poor performance in 2006. However, widespread genericization is threatening to stifle future growth in this class.
Competition intensifies for psoriasis treatments. New molecular entities are largely focused upon psoriasis indications. The market is likely to witness strong growth in the forecast period as anti-TNF therapies such as Enbrel and Humira maintain strong performances.
Shift in competitive landscape. With large pharma companies apparently neglecting their dermatology pipelines, small specialist players can build a market presence through strong lifecycle management strategies and targeted drug development.

Your questions answered

What will be the major growth indications and drivers in the dermatology area between 2008-13?
How will the competitive landscapes for acne, psoriasis, dermatitis, rosacea, viral, bacterial and fungal dermatological infection treatments change by 2013?
Which companies will become the key players in the dermatology market over the period 2008-2013?
How have recent launches from companies such as GSK, Galderma and Leo Pharma/Warner Chilcott performed?
Which pipeline products will be the growth drivers of the future?
How significant is the threat of generics to the global market?
What key trends and developments will influence the global dermatology market over 2008-13?

Content

The Dermatology Market Outlook to 2013
Executive Summary
- Overview and epidemiology of dermatological disorders
- Global market analysis
- Pipeline analysis
- Competitive landscape
Chapter 1 Scope and methodology
- Scope
- Methodology
Chapter 2 Overview and epidemiology of dermatological disorders
- Summary
- Introduction
- Acne
- Overview
- Epidemiology
- Forecast epidemiology
- Psoriasis
- Overview
- Epidemiology
- Forecast epidemiology
- Dermatitis
- Overview
- Epidemiology
- Forecast epidemiology
- Rosacea
- Overview
- Epidemiology
- Forecast epidemiology
- Infectious diseases of the skin
- Overview
- Viral infections of the skin
- Bacterial infections of the skin
- Fungal infections of the skin
- Epidemiology
- Viral infections of the skin
- Bacterial infections of the skin
- Fungal infections of the skin
- Forecast epidemiology
- Viral infections of the skin
- Bacterial infections of the skin
- Fungal infections of the skin
Chapter 3 Global market analysis
- Summary
- Introduction
- Market analysis by country
- Licensing trends
- Market analysis by drug class
- Leading brands dynamics
- Dermatology sales forecast to 2013
- Key events in the dermatology market
- Biologics expected to drive growth in the psoriasis market
- FDA requires class labeling and strengthened warnings for all four leading
- anti-TNF therapies
- Topical acne market moving towards combination products
- Black box warning for Elidel and Protopic to adversely impact growth
- Roches Roaccutane plagued by side-effect concerns and limited risk
- management programs
- Acne treatments
- Market analysis by drug class
- Leading acne treatment brands by drug class
- Key brands analysis
- Differine
- Roaccutane
- Acne treatment sales forecast to 2013
- Psoriasis treatments
- Market analysis by drug class
- Leading psoriasis treatment brands by drug class
- Key brands analysis
- Raptiva
- Soriatane
- Psoriasis treatment sales forecast to 2013
- Corticosteroid treatments
- Market analysis by drug class
- Leading corticosteroid treatment brands by drug class
- Key brands analysis
- Olux
- Corticosteroid treatment sales forecast to 2013
- Anti-infective treatments
- Market analysis by drug class
- Leading anti-infective treatment brands by drug class
- Key brands analysis
- Lamisil
- Bactroban
- Aldara
- Zovirax
- Anti-infective treatments sales forecast to 2013
- Non steroidal products
- Market analysis by drug class
- Non steroidal brands by drug class
- Key brands analysis
- Elidel
- Protopic
- Non steroidal treatments sales forecast to 2013
Chapter 4 Pipeline analysis
- Summary
- Introduction
- Key trends in R&D
- Celgenes apremilast may be an alternative to current anti-TNF therapies
- Intense competition in psoriasis, but voclosporin could compete on better
- side-effect profile and cost
- Collagenex (Galderma) licenses becocalcidol from QuatRx
- Reformulation products gaining traction
- Dermatology pipeline
- Leading drugs in development
- Profiles of key pipeline products
- Recently marketed drugs
- Altabax
- Desonate (desonide hydrogel)
- Humira
- Ziana
- Oracea
- Taclonex
- Drugs in registration
- Ustekinumab (CNTO1275)
- Panaclar/BG-12
- Drugs in Phase III clinical studies
- Voclosporin (ISA-237)
- ABT-874 (formerly J-695)
- Drugs in Phase II clinical studies
- Apremilast (CC-10004)
- COL-118
- Pipeline forecast
Chapter 5 Competitive landscape
- Summary
- Introduction
- Sales performance of leading players
- Detailed analysis of leading dermatology players
- Stiefel Labs
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Johnson & Johnson (J&J)
- Overview
- Sales focus by drug class
- R&D pipeline analysis
- Sanofi-Aventis
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Novartis
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- GlaxoSmithKline (GSK)
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Galderma
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Leo Pharma
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Bayer-Schering Pharma
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Schering-Plough
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
- Roche
- Overview
- Sales focus by drug class
- Marketed product portfolio
- R&D pipeline analysis
- Strategic and growth analysis
Chapter 6 Appendix
- IMS data
- D1A1 Topical dermatological anti-fungals
- D1A2 Systemic dermatological anti-fungals
- D1A3 Topical scalp anti-fungals
- D5A0 Topical anti-psoriasis products
- D5B0 Systemic anti-psoriasis products
- D5X0 Other non-steroidal products for inflammatory skin disorders
- D6A0 Topical antibiotics and/or sulphonamides
- D6D1 Topical anti-virals
- D6D9 Other topical products used in viral infections
- D7A0 Plain topical corticosteroids
- D7B1 Combinations of corticosteroids with anti-bacterials
- D7B2 Combinations of corticosteroids with anti-fungals
- D7B3 Combinations of corticosteroids with anti-bacterials
- D7B4 Other corticosteroid combinations
- D10A0 Topical anti-acne preparations
- D10B0 Oral anti-acne preparations
- Glossary
- Biologics
- Monoclonal antibody
- Anti-TNF therapies
- Atopic dermatitis
- Rosacea
- Psoriasis
- Pleuromutilin
- Psoriasis Area and Severity Index (PASI)
- Clinical Erythema Assessment (CEA)
- Index
List of Figures
- Figure 2.1: Mechanism of acne formation
- Figure 2.2: Disease progression and symptoms of acne
- Figure 2.3: Common forms of psoriasis
- Figure 2.4: Types of dermatitis
- Figure 2.5: Types of contact dermatitis
- Figure 2.6: Subtypes of rosacea
- Figure 2.7: Types of viral infections
- Figure 2.8: Types of bacterial infections
- Figure 2.9: Types of fungal infections
- Figure 3.10: Global dermatology market share by geography, 2007, US$m
- Figure 3.11: Sales of types of dermatology brands, 200607
- Figure 4.12: Prevailing R&D approaches, 2008
- Figure 4.13: Leading recently launched products and late-stage R&D in the dermatology market, 2008
- Figure 5.14: Market share of key players by sales value, 2007
- Figure 5.15: Projected market share of key players by sales value, 2013
- Figure 5.16: Market share and ranking of leading players in the global dermatology market, 2007 13
- Figure 5.17: Stiefel Labs dermatology sales by drug class, 2007
- Figure 5.18: J&Js dermatology sales by drug class, 2007
- Figure 5.19: Sanofi-Aventis dermatology sales by drug class, 2007
- Figure 5.20: Novartis dermatology sales by drug class, 2007
- Figure 5.21: GSKs dermatology sales by drug class, 2007
- Figure 5.22: Galdermas dermatology sales by drug class, 2007
- Figure 5.23: Leo Pharmas dermatology sales by drug class, 2007
- Figure 5.24: Bayer-Scherings dermatology sales by drug class, 2007
- Figure 5.25: Schering Ploughs dermatology sales by drug class, 2007
- Figure 5.26: Roches dermatology sales by drug class, 2007
- Table 2.1: Estimated prevalence of dermatological conditions across the seven major markets, 2007
- Table 2.2: Estimated prevalence of acne across the seven major markets, 2007
- Table 2.3: Forecast epidemiology of acne across the seven major markets, 200713
- Table 2.4: Estimated prevalence of psoriasis across the seven major markets, 2007
- Table 2.5: Forecast epidemiology of psoriasis across the seven major markets, 200713
- Table 2.6: Estimated prevalence of dermatitis across the seven major markets, 2007
- Table 2.7: Forecast epidemiology of dermatitis across the seven major markets, 200713
- Table 2.8: Estimated prevalence of rosacea across the seven major markets, 2007
- Table 2.9: Forecast epidemiology of rosacea across the seven major markets, 200713
- Table 2.10: Estimated prevalence of viral infections of the skin across the seven major markets, 2007
- Table 2.11: Estimated prevalence of bacterial infections of the skin across the seven major markets, 2007
- Table 2.12: Estimated prevalence of fungal infections of the skin across the seven major markets, 2007
- Table 2.13: Forecast epidemiology of viral infections of the skin across the seven major markets,
200713
- Table 2.14: Forecast epidemiology of bacterial infections of the skin across the seven major markets, 2007
- Table 2.15: Forecast epidemiology of fungal infections of the skin across the seven major markets, 200713
- Table 3.16: The global dermatology market by drug class 200607
- Table 3.17: Leading brands in the global dermatology market, 200607
- Table 3.18: Dermatology market sales forecast by drug class 200713
- Table 3.19: The global acne market by drug class, 200607
- Table 3.20: Leading acne treatments in the global dermatology market,
- Table 3.21: Anti-acne products sales forecast, 200713
- Table 3.22: The global psoriasis market by drug class, 200607
- Table 3.23: Leading psoriasis treatments in the global dermatology market, 200607
- Table 3.24: Anti-psoriasis sales forecast, 200713
- Table 3.25: The global corticosteroid market by drug class, 200607
- Table 3.26: Leading corticosteroid treatments in the global dermatology market, 200607
- Table 3.27: Corticosteroid treatments sales forecast, 200713
- Table 3.28: The global anti-infectives market by drug class, 200607
- Table 3.29: Leading anti-infective treatments in the global dermatology market, 200607
- Table 3.30: Anti-infective treatments sales forecast, 200713
- Table 3.31: Non steroidal treatments by drug class, 200607
- Table 3.32: Non steroidal treatments in the global dermatology market,
- Table 3.33: Other leading dermatology treatments sales forecast, 200713
- Table 4.34: Dermatology pipeline by indication and stage of development, 1H2008
- Table 4.35: An overview of Altabax
- Table 4.36: An overview of Desonate
- Table 4.37: Humira REVEAL data
- Table 4.38: Humira versus placebo
- Table 4.39: Humira versus placebo
- Table 4.40: An overview of Ziana
- Table 4.41: An overview of Oracea
- Table 4.42: An overview of Taclonex
- Table 4.43: An overview of Ustekinumab
- Table 4.44: An overview of Panaclar
- Table 4.45: An overview of Voclosporin (ISA-237)
- Table 4.46: An overview of ABT-874
- Table 4.47: An overview of Apremilast
- Table 4.48: An overview of COL-118
- Table 4.49: Dermatology disorders pipeline forecast, 200813 ($m)
- Table 5.50: Leading Players in the global dermatology market, 200713 ($m)
- Table 5.51: Stiefel Labs' leading dermatology product portfolio, 200607
- Table 5.52: J&Js leading dermatology product portfolio, 200607
- Table 5.53: Sanofi-Aventis leading dermatology product portfolio, 200607
- Table 5.54: Novartis leading dermatology product portfolio, 200607
- Table 5.55: Novartis dermatology R&D product pipeline, 2007
- Table 5.56: GSKs leading dermatology product portfolio, 200607
- Table 5.57: GSKs dermatology R&D product pipeline, 2007
- Table 5.58: Galdermas leading dermatology product portfolio, 200607
- Table 5.59: Leo Pharmas leading dermatology product portfolio, 200607
- Table 5.60: Leo Pharmas dermatology R&D product pipeline, 2007
- Table 5.61: Bayer Scherings leading dermatology product portfolio, 200607
- Table 5.62: Schering Ploughs leading dermatology product portfolio, 200607
- Table 5.63: Roches leading dermatology product portfolio, 200607